Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A new kind of treatment for diabetes being developed by biotechnology company MicroIslet has produced improved glycemic control over a six-month period in diabetic primates.
Subscribe to our email newsletter
The primates in the trial achieved the improved glycemic control after treatment with MicroIslet’s proprietary microencapsulated porcine islet transplantation treatment approach. Primates in the trial showed substantial reduction in the need for insulin to control blood glucose levels.
Additionally, this breakthrough was achieved without the need for chronic immunosuppressive therapy to prevent rejection of the transplanted insulin-producing islets.
According to MicroIslet, this six-month milestone represents an “industry first in the effort to establish a more effective treatment for diabetes.”
“We believe that with this positive data, we are setting the cornerstone for a new and vastly improved treatment for diabetes, which has reached an epidemic stage, afflicting an estimated 21 million Americans, including over six million who are undiagnosed,” commented Dr James Gavin, president and CEO of MicroIslet.